Comparison of Merus N.V. (MRUS) and Sage Therapeutics Inc. (NASDAQ:SAGE) – MS Wkly

Both Merus N.V. (NASDAQ:MRUS) and Sage Therapeutics Inc. (NASDAQ:SAGE) are Biotechnology companies, competing one another. We will compare their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Valuation and Earnings

Table 1 highlights Merus N.V. and Sage Therapeutics Inc.s gross revenue, earnings per share and valuation.

Profitability

Table 2 has Merus N.V. and Sage Therapeutics Inc.s return on equity, return on assets and net margins.

Liquidity

Merus N.V.s Current Ratio is 6.4 while its Quick Ratio is 6.4. On the competitive side is, Sage Therapeutics Inc. which has a 20.1 Current Ratio and a 20.1 Quick Ratio. Sage Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to Merus N.V.

Analyst Ratings

The table shown features the ratings and recommendations for Merus N.V. and Sage Therapeutics Inc.

Merus N.V.s consensus price target is $20, while its potential upside is 22.17%. Competitively the consensus price target of Sage Therapeutics Inc. is $195, which is potential 39.59% upside. The information presented earlier suggests that Sage Therapeutics Inc. looks more robust than Merus N.V. as far as analyst view.

Institutional & Insider Ownership

Roughly 65.8% of Merus N.V. shares are owned by institutional investors while 98.75% of Sage Therapeutics Inc. are owned by institutional investors. Insiders owned 30.47% of Merus N.V. shares. Competitively, insiders own roughly 1.2% of Sage Therapeutics Inc.s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Merus N.V. has weaker performance than Sage Therapeutics Inc.

Summary

On 6 of the 11 factors Merus N.V. beats Sage Therapeutics Inc.

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, gastric, and ovarian cancers. The company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies, as well as developing MCLA-158, a bispecific antibody candidate, which is designed to bind to cancer stem cells for the potential treatment of colorectal cancer. Its pre-clinical bispecific antibody candidates include MCLA-134 and MCLA-145, as well as other early research projects. The company has a strategic collaboration with Incyte and ONO Pharmaceutical Co., Ltd. to develop bispecific antibody candidates based on Biclonics technology platform. Merus N.V. was founded in 2003 and is headquartered in Utrecht, the Netherlands.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE), as well as for the treatment of post-partum depression (PPD). The companys product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and Parkinsons diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus. In addition, its product pipeline that are in preclinical stage comprises SAGE-105, a novel neuroactive steroid for the treatment of orphon epilepsies; SAGE-324, a novel neuroactive steroid for the treatment of GABA hypofunction; and SAGE-718, a novel oxysterol-based positive allosteric modulator of NMDA receptors for the treatment of cerebrosterol deficit disorders, anti-NMDA receptor encephalitis, and NMDA hypofunction. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Go here to see the original:
Comparison of Merus N.V. (MRUS) and Sage Therapeutics Inc. (NASDAQ:SAGE) - MS Wkly